Invesaro

Stocks Health care PPBT

NASDAQ · Health care

Purple Biotech Ltd. (PPBT)

It posted a net loss of $26.4M. In fiscal 2025 capital spending exceeded operating cash flow by $5.7M. At December 31, 2025 it held $8.7M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 19, 2026.

Price
$1.51
+2.03% on the day · September 25, 2026
52-week range $1.16 to $14.10
Market cap
$2.5M

What Purple Biotech Ltd. does

Purple Biotech Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PPBT.

Revenue and profit by year

Revenue
FY18: $1M $1M FY18FY19: $1M $1M FY19FY20: $1M $1M FY20
Net income
FY18: $5.2M $5.2M FY18FY19: $5.4M $5.4M FY19FY20: $28.7M $28.7M FY20FY21: $17.8M $17.8M FY21FY22: -$21.7M -$21.7M FY22FY23: -$19.9M -$19.9M FY23FY24: -$7.2M -$7.2M FY24FY25: -$26.4M -$26.4M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025n/an/a-$26.4M$0.03-$5.7M
2024n/an/a-$7.2M$4.99n/a
2023n/a-$22.3M-$19.9M$17.96-$19.9M
2022n/a-$22.6M-$21.7M$23.97-$16.8M
2021n/a-$17.9M$17.8M$23.29-$489K
2020$1M-$12.6M$28.7M$0.00$1.5M

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Purple Biotech Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 9, 2026
  2. September 2, 2026
  3. August 14, 2026
  4. August 10, 2026
  5. August 7, 2026
  6. July 29, 2026
  7. June 23, 2026
  8. June 11, 2026
  9. May 20, 2026
  10. May 15, 2026

Recent insider filings (Forms 3, 4 and 144): 8, the latest on April 17, 2026. Insider transactions on SEC

Who owns PPBT

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

HolderOf classSharesFiled
Mitchell P. Kopin13G, passive with 2 related filers 9.99% 282,513,535 May 13, 2026

Latest filings below 5%: G1 Execution Services, LLC 1.4% (August 14, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about PPBT

What does Purple Biotech Ltd. do?

Purple Biotech Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PPBT.

Is Purple Biotech Ltd. profitable?

No. In fiscal 2025 it reported a net loss of $26.4M.

When did Purple Biotech Ltd. last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 19, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 9, 2026.

Similar companies

Compare PPBT with

Compare PPBT with any company

Follow PPBT

Get an email when Purple Biotech Ltd. files with the SEC: results, executive changes, material agreements and annual reports.

Follow PPBT: get an email when it files

Where the numbers come from

Financial figures are the values Purple Biotech Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.